Yaxing Biomedical Lands Around $8.8 Million In Series Pre-A Financing

Yaxing Biomedical just received around 8.8 million dollars in Series Pre-A financing, this round of financing was led by Pan-Lin Asset Management and followed by Teng Yuan Capital.

Yaxing Biomedical is the leading research and development platform for tumor microenvironment drugs in China. By developing a drug delivery system that is activated in the tumor microenvironment, this system can reduce the toxicity of these drugs. Yaxing Biomedical spend a long time to develop drugs that based on tumor microenvironment activation, and its first product has already entered the clinical trial stage.

Company founder Chen Liu indicates that this drug delivery system can reduce the toxicity of traditional drugs this has an urgent need in tumor immunotherapy and other diseases. This product would help patients around the world.

Pan-Lin Asset Management is a professional RMB private equity fund investment management platform that is mainly engaged in assets management in equity investment and post-investment stages.

Teng Yuan Capital is a specialty fund focusing on investing in the field of health care and biotech industries, with total equity of 2 billion RMB.